

# Haoqiang Ying

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7475902/publications.pdf>

Version: 2024-02-01

67  
papers

13,868  
citations

71102

41  
h-index

98798

67  
g-index

71  
all docs

71  
docs citations

71  
times ranked

21988  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. <i>Cell</i> , 2012, 149, 656-670.	28.9	1,587
2	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. <i>Nature</i> , 2013, 496, 101-105.	27.8	1,562
3	Pancreatic cancers require autophagy for tumor growth. <i>Genes and Development</i> , 2011, 25, 717-729.	5.9	1,224
4	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. <i>Nature</i> , 2014, 514, 628-632.	27.8	998
5	Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. <i>Science</i> , 2007, 318, 287-290.	12.6	849
6	Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. <i>Nature</i> , 2016, 536, 479-483.	27.8	843
7	p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. <i>Nature</i> , 2008, 455, 1129-1133.	27.8	658
8	Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. <i>Cell</i> , 2014, 158, 185-197.	28.9	553
9	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. <i>Nature Medicine</i> , 2019, 25, 628-640.	30.7	476
10	FoxOs Cooperatively Regulate Diverse Pathways Governing Neural Stem Cell Homeostasis. <i>Cell Stem Cell</i> , 2009, 5, 540-553.	11.1	418
11	Genetics and biology of pancreatic ductal adenocarcinoma. <i>Genes and Development</i> , 2016, 30, 355-385.	5.9	416
12	Antitelomerase Therapy Provokes ALT and Mitochondrial Adaptive Mechanisms in Cancer. <i>Cell</i> , 2012, 148, 651-663.	28.9	240
13	MDM2 Promotes Proteasome-Dependent Ubiquitin-Independent Degradation of Retinoblastoma Protein. <i>Molecular Cell</i> , 2005, 20, 699-708.	9.7	239
14	PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas. <i>Cancer Cell</i> , 2010, 17, 497-509.	16.8	224
15	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. <i>Nature</i> , 2017, 542, 119-123.	27.8	209
16	PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF- $\kappa$ B Cytokine Network. <i>Cancer Discovery</i> , 2011, 1, 158-169.	9.4	186
17	Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. <i>Nature Communications</i> , 2018, 9, 4945.	12.8	170
18	Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1283-1299.	8.2	163

#	ARTICLE	IF	CITATIONS
19	KRAS-related proteins in pancreatic cancer. , 2016, 168, 29-42.		151
20	Oncogenic Signaling Pathways Activated in DMBA-Induced Mouse Mammary Tumors. Toxicologic Pathology, 2005, 33, 726-737.	1.8	143
21	Neuroplastic Changes Occur Early in the Development of Pancreatic Ductal Adenocarcinoma. Cancer Research, 2014, 74, 1718-1727.	0.9	140
22	Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19372-19377.	7.1	134
23	FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO Journal, 2013, 32, 2589-2602.	7.8	130
24	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature, 2019, 568, 410-414.	27.8	129
25	Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Cancer Discovery, 2020, 10, 608-625.	9.4	119
26	Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6912-6917.	7.1	109
27	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366.	27.8	105
28	Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight, 2019, 4, .	5.0	102
29	STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes and Development, 2012, 26, 1459-1472.	5.9	101
30	microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF- $\beta$ 2 Signaling in Glioblastoma. Cancer Discovery, 2012, 2, 736-749.	9.4	99
31	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science, 2021, 373, eabj0486.	12.6	99
32	Recent insights into the biology of pancreatic cancer. EBioMedicine, 2020, 53, 102655.	6.1	78
33	Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nature Communications, 2017, 8, 14437.	12.8	77
34	Glucose Metabolism in Pancreatic Cancer. Cancers, 2019, 11, 1460.	3.7	74
35	<scp>ATRX</scp> loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO Journal, 2019, 38, e96659.	7.8	71
36	The Central Acidic Domain of MDM2 Is Critical in Inhibition of Retinoblastoma-mediated Suppression of E2F and Cell Growth. Journal of Biological Chemistry, 2004, 279, 53317-53322.	3.4	69

#	ARTICLE	IF	CITATIONS
37	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 1091-1101.	0.9	68
38	Expression of Long Noncoding RNA <i>YIYA</i> Promotes Glycolysis in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 4524-4532.	0.9	59
39	Targeting Retinoblastoma Protein for Degradation by Proteasomes. <i>Cell Cycle</i> , 2006, 5, 506-508.	2.6	58
40	Functional annotation of rare gene aberration drivers of pancreatic cancer. <i>Nature Communications</i> , 2016, 7, 10500.	12.8	58
41	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. <i>Cancer Cell</i> , 2018, 33, 752-769.e8.	16.8	58
42	YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. <i>JCI Insight</i> , 2019, 4, .	5.0	46
43	Hyaluronic acid fuels pancreatic cancer cell growth. <i>ELife</i> , 2021, 10, .	6.0	45
44	Inhibition of RelB by 1,25-dihydroxyvitamin D <sub>3</sub> promotes sensitivity of breast cancer cells to radiation. <i>Journal of Cellular Physiology</i> , 2009, 220, 593-599.	4.1	43
45	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. <i>Nature Communications</i> , 2021, 12, 7041.	12.8	43
46	DNA-Binding and Transactivation Activities Are Essential for TAp63 Protein Degradation. <i>Molecular and Cellular Biology</i> , 2005, 25, 6154-6164.	2.3	42
47	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. <i>Cell Reports</i> , 2020, 33, 108293.	6.4	39
48	Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms. <i>Cancer Research</i> , 2015, 75, 2109-2119.	0.9	33
49	Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. <i>ELife</i> , 0, 11, .	6.0	32
50	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2021, 12, 4626.	12.8	31
51	Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPAR $\gamma$ . <i>Nature Communications</i> , 2022, 13, 2665.	12.8	25
52	Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. <i>Cancer Research</i> , 2021, 81, 4054-4065.	0.9	24
53	KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. <i>Cancer Letters</i> , 2021, 517, 66-77.	7.2	22
54	Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors. <i>Journal of Cellular Biochemistry</i> , 2005, 95, 875-884.	2.6	21

#	ARTICLE	IF	CITATIONS
55	The MDM2 RING finger is required for cell cycle-dependent regulation of its protein expression. FEBS Letters, 2003, 544, 218-222.	2.8	17
56	Deregulation of Cdc2 kinase induces caspase-3 activation and apoptosis. Biochemical and Biophysical Research Communications, 2003, 302, 384-391.	2.1	15
57	ZNF365 Promotes Stability of Fragile Sites and Telomeres. Cancer Discovery, 2013, 3, 798-811.	9.4	15
58	Rapamycin Inhibits IGF-1-Mediated Up-Regulation of MDM2 and Sensitizes Cancer Cells to Chemotherapy. PLoS ONE, 2013, 8, e63179.	2.5	14
59	Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Oncogene, 2021, 40, 6759-6771.	5.9	13
60	Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer. Oncogene, 2020, 39, 1152-1164.	5.9	12
61	Decoding the role of long noncoding RNAs in the healthy aging of centenarians. Briefings in Bioinformatics, 2021, 22, .	6.5	12
62	Inhibition of Cdc42 is essential for Mig-6 suppression of cell migration induced by EGF. Oncotarget, 2016, 7, 49180-49193.	1.8	12
63	Targeting syndecan-1: new opportunities in cancer therapy. American Journal of Physiology - Cell Physiology, 2022, 323, C29-C45.	4.6	11
64	Cancer signaling: when phosphorylation meets methylation. Cell Research, 2014, 24, 1282-1283.	12.0	9
65	A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics. International Journal of Cancer, 2020, 146, 2822-2828.	5.1	9
66	The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. American Journal of Cancer Research, 2020, 10, 2621-2634.	1.4	8
67	Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling. Cancer Research, 2021, 81, 1528-1539.	0.9	5